Sei Investments Co. Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sei Investments Co. lowered its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 77.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,964 shares of the biotechnology company’s stock after selling 47,487 shares during the quarter. Sei Investments Co.’s holdings in Sarepta Therapeutics were worth $2,206,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SRPT. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors grew its stake in Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after acquiring an additional 319,444 shares during the last quarter. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 5.6% in the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on SRPT shares. Piper Sandler decreased their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Royal Bank of Canada raised their target price on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the company an “outperform” rating in a report on Friday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Needham & Company LLC reiterated a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. Finally, Citigroup lowered their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $187.44.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, Director Michael Andrew Chambers bought 37,038 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Up 1.4 %

Sarepta Therapeutics stock opened at $120.40 on Friday. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The firm has a market cap of $11.38 billion, a P/E ratio of 1,094.55 and a beta of 0.82. The business has a fifty day moving average of $133.01 and a two-hundred day moving average of $132.68. Sarepta Therapeutics, Inc. has a twelve month low of $55.25 and a twelve month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the business posted ($0.27) EPS. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.